Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Genitourinary Cancers
How would you treat a patient with a post prostatectomy biochemical and pelvic nodal recurrence with a BLM mutation?
Related Questions
How would you manage a patient who developed an intraprostatic abscess after SpaceOAR injection, prior to starting radiation?
For a patient with a rising PSA after prostatectomy with seminal vesicles being negative for disease at surgery, do you ever treat the prostate bed and seminal vesicle bed with different doses in an SIB plan?
As PARTIQoL was a negative study, what is the current role for proton therapy in the management of prostate cancer patients?
What is your preferred approach in a patient unable to fill their bladder during prostate radiotherapy?
Would you offer palliative radiation to a patient with hematuria from squamous metaplasia of the bladder that is not responding to endoscopic therapy?
Is there any evidence for amyloid/amyloidosis causing a spurious/false PSA reading?
What duration androgen deprivation do you recommend with salvage pelvic radiotherapy for pelvic node relapse after prostatectomy?
In asymptomatic patients with castrate resistant prostate cancer who have failed chemotherapy and have progressive vertebral body metastases, when do you prescribe lutetium-177 vs prophylactic spinal radiation?
How do you approach elective nodal irradiation in muscle-invasive bladder cancer?
For recurrent prostate cancer after prostatectomy with soft tissue mass in the prostate fossa, is hypofractionation an option or is standard fractionation recommended?
